1. Introduction {#sec1-molecules-22-01617}
===============

Liver diseases, including viral hepatitis, fatty liver, liver fibrosis, cirrhosis, and liver cancer, are major diseases threatening human health and are the leading cause of deaths worldwide \[[@B1-molecules-22-01617]\]. Although there has been remarkable progress in the treatment of liver diseases over the last several decades, most of the therapies still do not yield satisfactory outcomes in patients \[[@B2-molecules-22-01617]\]. In view of the scarce treatment options and significant adverse effects caused by conventional chemical agents, novel prophylactic and therapeutic agents against liver disease are urgently needed \[[@B3-molecules-22-01617]\].

*Fructus schisandrae* (Wuweizi in Chinese), the fruit of *Schisandra chinensis* (Turcz.) Baill., is a traditional herbal medicine, which is believed to be liver tonic in China, Japan, and Russia \[[@B4-molecules-22-01617]\]. According to the theories of traditional Chinese medicine (TCM), Wuweizi can be used for treating Liver and Kidney Deficiency of Yin or Yang syndrome \[[@B5-molecules-22-01617]\]. Modern pharmacological study showed that Wuweizi might exhibit various therapeutic effects, such as hepatoprotection, anti-inflammation, and antioxidant properties \[[@B4-molecules-22-01617],[@B6-molecules-22-01617],[@B7-molecules-22-01617],[@B8-molecules-22-01617]\]. Recent studies demonstrated that the extract from Wuweizi could alleviate hepatic cholesterol and triglyceride levels, and retard the development of fatty liver in rodents given high-fat diets \[[@B9-molecules-22-01617]\]. Wuweizi extract could also attenuate mitochondrial Ca^2+^ loading and reduce the sensitivity of hepatic mitochondria to Ca^2+^-dependent MPT caused by carbon tetrachloride \[[@B10-molecules-22-01617]\]. In addition, Wuweizi could enhance both mitochondrial and cellular glutathione levels and antioxidant status by mediating glutathione synthesis and GPx levels, thus reducing ROS and protecting the tissues from oxidative stress in both in vitro and in vivo studies. Although several potential active components of Wuweizi have been reported, a holistic understanding of the molecular mechanisms responsible for their hepatoprotective effects still needs further exploration.

To comprehensively assess herbal pharmacological effects, network pharmacology has been introduced in recent years for exploring the molecular mechanisms of TCMs \[[@B11-molecules-22-01617],[@B12-molecules-22-01617]\]. With a deeply curated network map that describes interactions among molecules, researchers can carry out network-based screening to systematically identify target proteins of herbal medicines and to assess their impacts. Thus, network-based screening appears promising for secondary development of traditional Chinese herbal medicines and mechanisms prediction. Various bioinformatics resources including biological databases and molecular docking software have been developed in recent years, allowing a great opportunity for meeting the demands of rapid systematic screening \[[@B13-molecules-22-01617],[@B14-molecules-22-01617],[@B15-molecules-22-01617]\]. In this study, a network pharmacology study of Wuweizi was established through molecular docking and network analysis based on current identified active components of Wuweizi and potential targets associated with liver diseases. The study may provide a powerful tool for exploring the active mechanisms of TCMs and discovering novel bioactive ingredients of Wuweizi.

2. Results and Discussion {#sec2-molecules-22-01617}
=========================

2.1. Potential Biological Effect of Fructus Schisandrae on Liver Disease Predicted by Network Pharmacological Analysis {#sec2dot1-molecules-22-01617}
----------------------------------------------------------------------------------------------------------------------

In multi-compound medicinal herbs like Wuweizi, many compounds that lack appropriate pharmaceutical properties are believed to fail in reaching the cellular targets; thus, these compounds exhibit limited efficacy that can be neglected. We have identified a total of 117 potentially active chemicals in Wuweizi ([Table S1](#app1-molecules-22-01617){ref-type="app"}). The targets of these active chemicals of Wuweizi were predicted through molecular docking. To further illuminate the relationship between the effective compounds and potential targets, a compound--target network was built through network analysis. The compound and protein interaction analysis results showed that a total of 21 intracellular targets were predicted to interact with the 8 ingredients of Wuweizi ([Figure 1](#molecules-22-01617-f001){ref-type="fig"}). This network represents a global view of the potential compounds (pink triangles) and targets (blue rectangles) in Wuweizi, and it comprised 29 nodes (8 potential compounds and 21 potential targets) and 46 edges (compound--target interactions). The degree of nodes is a key topological parameter that characterizes the most influential nodes in a network, and we used it to further determine the importance of active components and liver disease targets \[[@B16-molecules-22-01617],[@B17-molecules-22-01617]\]. Those high-degree nodes in the network, which had more compound--target interactions, are likely to play a more important role in liver diseases \[[@B16-molecules-22-01617]\]. Our network analysis results showed that various candidate compounds in Wuweizi were linked to multiple targets, which might exhibit potent hepatoprotective effects. Among the 8 candidate compounds, schisantherin A exhibited the largest number of potential hepatoprotective targets connections (degree = 9), followed by schisandrin B (degree = 6), schisandrol B (degree = 6), kadsurin (degree = 4), wuweizisu C (degree = 4), gomisin A (degree = 4), gomisin G (degree = 2), and angeloylgomisin (degree = 1). For the 21 potential hepatoprotective targets, the network showed CYP2E1 had the largest number of compound--target interactions (schisandrin B, kadsurin, schisantherin A, wuweizisu C, gomisin A, and gomisin G), followed by PPARα (schisantherin A, wuweizisu C, and gomisin A), and AMPK (angeloylgomisin, gomisin A, and gomisin G). The remaining 18 targets showed interactions with only one or two compounds. The information of 21 potential hepatoprotective targets in Wuweizi can be found in [Table 1](#molecules-22-01617-t001){ref-type="table"}, where all the data were manually collected and integrated from the STITCH, TTD, PharmGKB, and CTD databases. For the 8 potential active chemicals in Wuweizi, some of them have been confirmed by experimental studies. For example, schisandrol B and kadsurin can inhibit CYP2E1 in rat primary hepatocytes and oxidize xenobiotics, such as toxins or drugs, and remove them from the body \[[@B18-molecules-22-01617]\]. Schisantherin A treatment can suppress the enzymatic activities of several CYP450 isoforms, which are related to acetaminophen bioactivation, such as CYP2E1, CYP1A2, and CYP3A11, and further decreased the formation of acetaminophen toxic intermediate *N*-acetyl-*p*-benzoquinone imine (NAPQI) in mouse microsomal incubation system. This study demonstrated that schisantherin A exhibited significant protective actions toward acetaminophen-induced liver injury, which was partially associated with the inhibition of CYP-mediated acetaminophen bioactivation \[[@B19-molecules-22-01617]\]. A recent study showed that gomisin A exhibited significant anti-hepatotoxic action by oral application, hypolipidemic (mainly triglyceridemic) and liver protein synthesis-facilitating actions. The enlargement of the liver seen with treatment of gomisin A is the adaptive hypertrophy, which is due to the induction of drug-metabolizing enzymes \[[@B20-molecules-22-01617]\]. In addition, administration of gomisin G to high-fat-diet-induced obese mice decreased liver weight, hepatic triglyceride (TG) accumulation, and cytoplasmic lipid droplets. These findings demonstrate that Gomisin activated the AMPK pathway and ameliorated HFD-induced hepatic steatosis \[[@B21-molecules-22-01617]\]. Wuweizisu C has also been widely studied by previous researches. It could dose-dependently inhibit fatty degeneration and decrease serum triglyceride. These researches suggested that wuweizisu C could be protective on hepatocellular phenomena such as cell necrosis, fatty degeneration, inflammatory cell infiltration, etc., on human hepatitis \[[@B22-molecules-22-01617]\]. Wuweizisu C also exhibited remarkable antihepatotoxic effects in CCl~4~-induced cytotoxicity, indicating that anti-oxidative action plays an important role in the antihepatotoxic activity of wuweizisu C and Wuweizi \[[@B23-molecules-22-01617]\].

The compound--target network related to hepatoprotective mechanism of Wuweizi in liver disease was shown in the network plotting. This network represents a global view of the potential compounds (pink triangles) in Wuweizi and their intracellular targets (blue rectangles) for liver disease. The network comprised 29 nodes (8 potential compounds and 21 potential targets) and 46 edges (compound--target interactions).

2.2. Potential Hepatoprotective Molecular Mechanism of Wuweizi {#sec2dot2-molecules-22-01617}
--------------------------------------------------------------

The potential hepatoprotective mechanisms of Wuweizi were further analyzed by above network pharmacology study. Our results demonstrated that multiple components in Wuweizi could target various intracellular genes associated with liver diseases, especially for fatty liver disease ([Figure 2](#molecules-22-01617-f002){ref-type="fig"}). CYP2E1, the key node in our network plotting, may play a pivotal role in hepatoprotective effects of Wuweizi. Previous studies showed that several risk factors such as alcohol and toxics could induce CYP2E1 activation and further increase hepatic oxidative stress \[[@B24-molecules-22-01617]\]. The reactive oxygen species (ROS) generated by CYP2E1 may lead to the production of reactive aldehydes with potent pro-inflammatory properties \[[@B25-molecules-22-01617]\]. Oxidative stress increases NF-κB activation, thus enhancing the expression of COX-2 and iNOS. The upregulation of COX-2 expression causes the enhanced production of PGE2, which functions through its receptors (EP2 and/or EP4) in hepatocytes to increase the accumulation of triglycerides and further promote the development of fatty liver disease \[[@B26-molecules-22-01617],[@B27-molecules-22-01617]\]. Furthermore, CYP2E1 may be directly associated with the development of drug-induced liver injury during oxidative stress. Inhibiting CYP2E1 activity resulted in a decrease in the production of reactive oxygen species (ROS) during thioacetamide (TAA) \[[@B28-molecules-22-01617]\] or isonicotinyl hydrazine (INH) metabolism \[[@B29-molecules-22-01617]\]. Thus, the regulation of CYP2E1 activity by Wuweizi (schisandrin B, kadsurin, schisantherin A, wuweizisu C, gomisin A, and gomisin G) may inhibit hepatic lipid peroxidation and alleviate hepatic injury.

The network results demonstrated that multiple components in Wuweizi can target various intracellular genes associated with liver disease, especially for fatty liver disease. The CYP2E1, PPARα, and AMPK genes and related pathway may play a pivotal role in the hepatoprotective effects of Wuweizi.

Peroxisome proliferator-activated receptor alpha (PPARα), another key node in our network pharmacology study, can modulate lipid peroxidation in fatty liver disease. PPARα is a kind of nuclear receptor proteins, and important transcription factors in the regulation of some enzymes in the β-oxidation pathway. Previous studies showed that PPARα expression was downregulated in alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) in human liver \[[@B30-molecules-22-01617]\]. Activating PPARα in liver can also prevent acetaminophen-induced liver damage by upregulating mitochondrial glutathione and downregulating fatty acyl-carnitines concentration in blood \[[@B31-molecules-22-01617]\]. In addition, during chronic alcoholic liver injury, PPARα also protects liver tissue by activating fatty acid β-oxidation related pathway \[[@B30-molecules-22-01617]\]. Although PPARα has no direct effects to hepatic lipid metabolism, the transcription level of several PPARα downstream target genes such as acyl-CoA oxidase (ACO) and carnitine palmitoyltransterase-1 (CPT-1) may play a critical role in preventing ALD and NAFLD by regulating mitochondrial and fatty acid β-oxidation \[[@B32-molecules-22-01617]\]. In addition, PPARα can induce a high expression of Acyl-CoA Oxidase (ACO) and carnitine palmitoyltransferase 1 (CPT-1) in adipose tissue and improve glucose homeostasis \[[@B33-molecules-22-01617]\]. Previous studies showed that Wuweizi extract prevented the ethanol-induced decrease in PPARα expression and resulted in a significant decrease in intracellular lipid accumulation in hepatocytes along with a decrease in serum TG levels, and it reversed fatty liver to normal conditions \[[@B34-molecules-22-01617]\]. Our network pharmacology study indicated that the potential active components of Wuweizi such as schisantherin A, wuweizisu C, and gomisin A may exhibit preventive ability for fatty liver disease through modulating the activity of PPARα and regulating the expression of several key genes in mitochondrial and fatty acid β-oxidation \[[@B35-molecules-22-01617]\].

AMP-activated protein kinase (AMPK) may also play a major role in the control of hepatic injury by Wuweizi according to our network results. AMPK integrates nutritional and hormonal signals to promote energy balance by switching on catabolic pathways and switching off ATP-consuming pathways, both by short-term effects on phosphorylation of regulatory proteins and by long-term effects on gene expression. Activating AMPK in liver leads to the stimulation of fatty acid oxidation and inhibition of lipogenesis, glucose production as well as protein synthesis \[[@B36-molecules-22-01617]\]. A previous study showed that enhanced phosphorylation of AMPK can inhibit the accumulation and nuclear translocation of mature sterol regulatory element-binding protein 1 (SREBP-1) and subsequently decreased the mRNA levels of lipogenic genes including acc1, fas, and scd1 \[[@B37-molecules-22-01617]\]. Another study also confirmed that the decreased phosphorylation of AMPK could increase maturation of SREBP-1 and expression of SREBP-responsive genes in the rat liver, and thus inhibit lipid accumulation in rat hepatocytes and human hepatoma cell lines \[[@B38-molecules-22-01617]\]. Activating the phosphorylation levels of AMPK can also inhibit Acetyl-CoA Carboxylase (ACC) and increase CPT-1 expression to reduce hepatic lipid accumulation \[[@B39-molecules-22-01617]\]. In addition, activation of AMPK can reduce the expression of hepatocyte nuclear factor 4α (HNF-4α) and decrease hepatic fatty acid synthesis \[[@B40-molecules-22-01617]\].

Some of the in silico data in our study have been further checked and proved by previous experimental data based on literature research. For example, a recent study results of Western blot indicated that schisandrin B can inhibit cell proliferation by downregulating proliferating cell nuclear antigen (PCNA) and induce cell apoptosis in HCC cells \[[@B41-molecules-22-01617]\]. Incubation with schisandrin B for 6 h caused optimal and dose-dependent increases in cellular 25 kilodalton heat shock proteins (Hsp25) activation at 16 h post-drug exposure in AML12 hepatocytes \[[@B42-molecules-22-01617]\]. Another study found that gomisin A could activate AMP-activated protein kinase (AMPK) and exerts therapeutic effects on liver X receptor (LXR)- or palmitic acid (PA)-induced triglyceride (TG) accumulation in HepG2 cells \[[@B21-molecules-22-01617]\]. These biological results further confirmed the potential prospects of our in silico method in exploring the hepatoprotective mechanisms of Wuweizi.

3. Materials and Methods {#sec3-molecules-22-01617}
========================

3.1. Database Construction and ADME Screening of Wuweizi Ingredients {#sec3dot1-molecules-22-01617}
--------------------------------------------------------------------

All of the known ingredients of Wuweizi were manually collected from related literature and two phytochemical databases: Traditional Chinese Medicine Systems Pharmacology Database (TCMSP, <http://ibts.hkbu.edu.hk/LSP/tcmsp.php>) and TCM Database\@Taiwan (<http://tcm.cmu.edu.tw/>). An in silico integrative model\~ADME was used to select the ingredients with favorable pharmacokinetics properties. The ADME system used in this study included oral bioavailability (PreOB) and Caco-2 permeability (PreCaco-2) prediction. Oral bioavailability (OB) is one of the most vital pharmacokinetic properties of orally administered drugs as it plays an important role for the efficiency of the drug delivery to the systemic circulation \[[@B43-molecules-22-01617],[@B44-molecules-22-01617]\] Here, a reliable in silico screening model (OBioavail 1.1) was employed in OB value calculation of the constituents in Wuweizi. This model was constructed based on 805 structurally diverse drugs and drug-like molecules. Multiple linear regression, partial least square, and support vector machine methods were applied during this model building, ending up with determination coefficient (*R*^2^) = 0.80 and standard error of estimate (*SEE*) = 0.31 for test sets \[[@B45-molecules-22-01617],[@B46-molecules-22-01617]\]. In addition, for orally administered drugs, another pivotal problem is their movement across the intestinal epithelial barrier, which determines the rate and extent of human absorption and ultimately affects its bioavailability \[[@B47-molecules-22-01617]\]. Thus, a preCaco-2 model was used to predict the drug absorption. The phytochemical information of the compounds with their Caco-2 permeability properties were explored using the TCMSP database, the detailed parameters' information, screening criteria, and calculation can be obtained from TCMSP website (<http://ibts.hkbu.edu.hk/LSP/tcmsp.php>). Finally, compounds values where OB ≥ 30% and Caco2 ≥ 0.4 cm/s were regarded as active ingredients for further study. It is worth noting that the OB value of schisantherin A and schisandrin B are lower than 30%, but both of them have been widely expected to be the active components in Wuweizi \[[@B48-molecules-22-01617],[@B49-molecules-22-01617],[@B50-molecules-22-01617]\]. Thus, these two compounds were also regarded as bioactive compounds for further analysis.

3.2. Preparation of Potential Targets and Ligand Structures {#sec3dot2-molecules-22-01617}
-----------------------------------------------------------

The candidate proteins related to liver diseases were data-mined from literatures and public database sources, including PubMed ([www.PubMed.org](www.PubMed.org)), PubChem ([www.Pubchem.org](www.Pubchem.org)), DrugBank (<http://www.drugbank.ca/>), Potential Drug Target Database (<http://www.dddc.ac.cn/pdtd/>), Therapeutic Targets Database (<http://bidd.nus.edu.sg/group/ttd/>) and PharmGkb ([www.pharmgkb.org](www.pharmgkb.org)). As of today, up to 44 protein targets related to viral hepatitis, fatty liver, liver fibrosis, cirrhosis and liver cancer were obtained ([Table 1](#molecules-22-01617-t001){ref-type="table"}), and their corresponding X-ray crystallographic structures were directly downloaded from RCSB Protein Data Bank (<http://www.pdb.org/>).

3.3. Molecular Docking and Network Building {#sec3dot3-molecules-22-01617}
-------------------------------------------

All the docking studies were carried out using the protein--ligand complexes with crystal structures. Prior to the docking studies, the protein structures were prepared with Sybyl-X version 2.0 software (Tripos Associates Inc., St. Louis, MO, USA) \[[@B51-molecules-22-01617]\]. The preparation work includes affixing hydrogen atoms and removing co-crystallized ligands as well as water molecules from the protein--ligand complexes. All the amide moieties of glutamine and asparagine in the side chains were regulated to modify their connections with nearby residues and atoms. Then, we used the Surflex-Dock module of Sybyl-X to continue docking. The detailed docking operation process and reliability-validated assay strictly followed the software instruction manual. The targets with docking consensus score greater than 6.0 were selected as the potential targets for further analysis \[[@B52-molecules-22-01617],[@B53-molecules-22-01617],[@B54-molecules-22-01617]\]. The compound--target network was then constructed using Cytoscape 3.0.2 software (<http://www.cytoscape.org/>) based on the molecular docking score. In the network, nodes stand for compounds and targets, and edges represent the compound--target interactions.

4. Conclusions {#sec4-molecules-22-01617}
==============

In this study, a compound--target network was constructed through molecular docking and network analysis. The network predicted the underlying mechanism of hepatoprotective effect of Wuweizi as a therapeutic approach to treat liver diseases, especially for fatty liver disease. This study demonstrated that a network pharmacology-based approach was useful for elucidation of the interrelationship between complex diseases such as liver diseases and Chinese herbal medicines interventions. Therefore, network pharmacology is a powerful tool for exploring the potential action mechanism of TCMs and new active ingredients. However, the current molecular docking results in our network pharmacology studies only provide indeterminate connections between chemicals and corresponding target genes. The accurate action modes between chemicals and target genes such as activation or inhibition are still not clear. To resolve this problem, experimental verification of the potential effective compounds after candidate screening is needed to validate the interactions between drugs and proteins based on theoretical predictions.
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molecules-22-01617-t001_Table 1

###### 

Forty-four protein targets related with viral hepatitis, fatty liver, liver fibrosis, cirrhosis, and liver cancer.

  Target Gene   Target Protein                                                                        Roles in Hepatoprotective Effects
  ------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  HLA-DRB1      major histocompatibility complex, class II, DQ beta 1                                 Anti-virus
  IFNL3         interferon lambda 3                                                                   Anti-virus
  HLA-DRB5      major histocompatibility complex, class II, DQ beta 5                                 Anti-virus
  IL6           Interleukin 6                                                                         Anti-virus
  NAT2          *N*-acetyltransferase 2                                                               Reduce antituberculosis drug-induced liver injury
  STAT3         signal transducer and activator of transcription 3                                    Regulate hepatic cell growth and apoptosis
  CYP2C9        Cytochrome P450 2C9                                                                   Regulate drug metabolism
  CYP2D6        Cytochrome P450 2D6                                                                   Regulate drug metabolism
  CYP3A         Cytochrome P450 3A                                                                    Regulate drug metabolism
  ITPA          inosine triphosphate pyrophosphatase                                                  Regulate drug metabolism
  UGT1A1        UDP glucuronosyltransferase family 1 member A1                                        Regulate drug metabolism
  UGT1A3        UDP glucuronosyltransferase family 1 member A3                                        Regulate drug metabolism
  CYP2E1        Cytochrome P450 2E1                                                                   Regulate drug metabolism
  HSPA1L        Heat shock 70 kDa protein 1L                                                          Regulate drug metabolism
  CYP2C19       Cytochrome P450 C19                                                                   Regulate drug metabolism
  PEMT          phosphatidylethanolamine *N*-methyltransferase                                        Regulate drug metabolism
  PNPLA3        Patatin-like phospholipase domain-containing protein 3                                Regulate fatty metabolism
  AKT1          v-akt murine thymoma viral oncogene homolog 1                                         Regulate lipid metabolism
  CYP2B6        cytochrome P450, family 2, subfamily B, polypeptide 6                                 Oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids
  CYP1B1        cytochrome P450, family 1, subfamily B, polypeptide 1                                 Oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids
  MMP2          matrix metallopeptidase 2                                                             Tissue repair and induce interstitial fibrosis
  PPARα         peroxisome proliferator-activated receptor alpha                                      Key regulator of lipid metabolism
  NFKBIA        nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha   On cellular stimulation by immune and proinflammatory responses
  AHSA1         activator of heat shock 90kDa protein ATPase homolog 1                                Involve in Grb2-p38 MAPK signaling pathway in fibrosis
  NQO1          NAD(P)H dehydrogenase, quinone 1                                                      Involve in alcohol detoxification pathways
  HMOX1         heme oxygenase (decycling) 1                                                          Alleviate liver inflammation and reduced oxidative stress
  ICAM-1        intercellular adhesion molecule 1                                                     Mediate adhesive interaction in fibrosis process
  MAPK1         mitogen-activated protein kinase 1                                                    Regulate cytoskeletal rearrangements in fibrosis process
  PRKCB         protein kinase C, beta                                                                Regulate oxidative stress-induced cell damage
  ACTA2         actin, alpha 2, smooth muscle, aorta                                                  Involve in myofibroblast cell motility during wound healing in liver
  SPZ1          spermatogenic leucine zipper 1                                                        The transcriptional factors of liver fatty acid binding protein
  COL1A1        collagen, type I, alpha 1                                                             Transcriptional repressor of the collagen
  BCL2          B-cell CLL/lymphoma 2                                                                 Regulate the response to mitochondrial damage and related oxidative damage
  CCND1         cyclin D1                                                                             Functions as a mediator of β-catenin during hepatocarcinogenesis
  RKIP          Raf kinase inhibitor protein                                                          Regulate carbon tetrachloride-induced apoptotic hepatic cell death
  HERC5         HECT and RLD domain containing E3 ubiquitin protein ligase 5                          Acts as a positive regulator of innate antiviral response in liver cells
  CDKN1A        cyclin-dependent kinase inhibitor 1A                                                  Regulate hepatic cell cycle in hepatocarcinogenesis
  mTOR          mammalian target of rapamycin                                                         Regulate hepatic cell autophagy
  EIF6          eukaryotic translation initiation factor 6                                            Regulate hepatocarcinogenesis by mediating cellular response to DNA damage.
  CASP3         caspase 3                                                                             Apoptosis inhibitory protein in hepatocarcinogenesis
  COL7A1        collagen, type VII, alpha 1                                                           Regulate fibrosis by impacts on extracellular matrix (ECM) proteins such as type IV collagen
  COL3A1        collagen, type III, alpha 1                                                           Regulate fibrosis by impacts on extracellular matrix (ECM) proteins such as type IV collagen
  HSP 25        25 kilodalton heat shock proteins                                                     Protect cells from oxidation stress
  TGFB1         transforming growth factor, beta 1                                                    Regulate liver cancer cells proliferation
  TIMP1         TIMP metallopeptidase inhibitor 1                                                     Tissue repair and induce interstitial fibrosis
  SOD1          superoxide dismutase 1                                                                Destroys radicals that are normally produced within the cells, such as oxidants
  RELA          v-rel reticuloendotheliosis viral oncogene homolog A                                  Involve in hepatic inflammation
  PCNA          Proliferating Cell Nuclear Antigen                                                    Inhibit HCC cell proliferation
  XBP-1         X-box-binding protein-1                                                               Protection against endoplasmic reticulum (ER) stress
  AMPK          AMP-activated protein kinase                                                          Regulate hepatic fatty acid oxidation
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